Literature DB >> 30165098

Dendrimer as a new potential carrier for topical delivery of siRNA: A comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA.

Palpandi Pandi1, Anjali Jain1, Nagavendra Kommineni1, Maksim Ionov2, Maria Bryszewska3, Wahid Khan4.   

Abstract

Topical delivery of siRNA is challenging task due to complex barrier property of stratum corneum and cationic lipid based carriers have been widely explored for this purpose due to improved permeation through skin. For gene delivery application, dendrimers are considered as efficient carrier due to their cationic nature and well-defined surface groups. However, they are not well explored for topical delivery. This work compares the suitability of PAMAM dendrimer with DOTAP liposome for topical delivery of siRNA against TNF-α. The particle size, zeta potential and entrapment efficiency of dendriplex were 99.80 ± 1.80 nm, 13.40 ± 4.84 mV and 98.72 ± 2.02% whereas for lipoplex were 174.80 ± 0.80 nm, 29.96 ± 0.51 mV and 94.99 ± 5.01% respectively. Both the formulations were stable in serum and in the presence of RNAse. TNF-α is inflammatory cytokine, hence the in vivo efficacy of developed formulations was determined using psoriatic plaque model. Results suggested improved phenotypic and histopathological features and reduced levels of IL-6, TNF-α, IL-17 and IL-22 for dendriplex and lipoplex treated groups in comparison to Imiquimod treated group. These findings suggest that dendrimer can be a potential carrier for topical gene delivery.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dendrimers; Liposomes; Psoriasis; RNA interference; TNF-α

Mesh:

Substances:

Year:  2018        PMID: 30165098     DOI: 10.1016/j.ijpharm.2018.08.024

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics.

Authors:  Nagavendra Kommineni; David Paul; Raju Saka; Wahid Khan; Satheeshkumar Nanjappan
Journal:  Nanotheranostics       Date:  2022-08-21

2.  In Vitro Anticancer Properties of Copper Metallodendrimers.

Authors:  Marcin Hołota; Jakub Magiera; Sylwia Michlewska; Małgorzata Kubczak; Natalia Sanz Del Olmo; Sandra García-Gallego; Paula Ortega; F Javier de la Mata; Maksim Ionov; Maria Bryszewska
Journal:  Biomolecules       Date:  2019-04-18

Review 3.  siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.

Authors:  Saman Sargazi; Rabia Arshad; Reza Ghamari; Abbas Rahdar; Ali Bakhshi; Sonia Fathi Karkan; Narges Ajalli; Muhammad Bilal; Ana M Díez-Pascual
Journal:  Cell Biol Int       Date:  2022-07-13       Impact factor: 4.473

Review 4.  Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs.

Authors:  Ana M Martins; Andreia Ascenso; Helena Margarida Ribeiro; Joana Marto
Journal:  Mol Neurobiol       Date:  2020-02-15       Impact factor: 5.590

Review 5.  Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.

Authors:  Robert Gironés Petit; Amanda Cano; Alba Ortiz; Marta Espina; Josefina Prat; Montserrat Muñoz; Patrícia Severino; Eliana B Souto; Maria L García; Montserrat Pujol; Elena Sánchez-López
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.